Evidence map›Paper›PMID 29971006›Full record

ArticleFrontiers in pharmacology2018

The Modulatory Properties of Li-Ru-Kang Treatment on Hyperplasia of Mammary Glands Using an Integrated Approach.

Shizhang Wei, Liqi Qian, Ming Niu, Honghong Liu, Yuxue Yang, Yingying Wang, Lu Zhang, Xuelin Zhou, Haotian Li, Ruilin Wang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Shizhang WeiDepartment of Pharmacy, 302 Hospital of People's Liberation Army, Beijing, China.
Liqi QianDepartment of Traditional Chinese Medicine, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China.
Ming NiuChina Military Institute of Chinese Medicine, 302 Hospital of People's Liberation Army, Beijing, China.
Honghong LiuDepartment of Integrative Medical Center, 302 Hospital of People's Liberation Army, Beijing, China.
Yuxue YangDepartment of Pharmacy, 302 Hospital of People's Liberation Army, Beijing, China.
Yingying WangDepartment of Pharmacy, 302 Hospital of People's Liberation Army, Beijing, China.
Lu ZhangDepartment of Pharmacy, 302 Hospital of People's Liberation Army, Beijing, China.
Xuelin ZhouDepartment of Pharmacy, 302 Hospital of People's Liberation Army, Beijing, China.
Haotian LiDepartment of Pharmacy, 302 Hospital of People's Liberation Army, Beijing, China.
Ruilin WangDepartment of Traditional Chinese Medicine, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China.
Kun LiDepartment of Pharmacy, 302 Hospital of People's Liberation Army, Beijing, China.
Yanling ZhaoDepartment of Pharmacy, 302 Hospital of People's Liberation Army, Beijing, China.
302 Military Hospital of China · CNFirst Affiliated Hospital of Chinese PLA General Hospital · CNChinese People's Liberation Army · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

hyperplasia of mammary glandsLi-Ru-Kangmetabolomicsmodulatory propertiesnetwork pharmacology

Identifiers

PMID29971006
PMCPMC6018463
OpenAlexW2807011811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.